Lung Cancer (Small Cell) OverviewTests used to look for cancer spreadWhen you breathe in
The 5-year survival of patients with small cell lung cancer is only 5%. The staging of small cell lung cancer is divided into limited stage and extensive stage (Box 64-3). Limited stage refers to disease that can be confined to one radiation port. At the time of presentation, ...
Small-celllung cancer(SCLC) is a disease in which cells in your lung begin growing out of control. It starts in nerve cells or cells that make hormones. About 10% to 15% of lung cancer cases are small-cell. The other kind is called non-small-cell lung cancer. They’re different in ...
OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.
Navigating treatment combinations in small-cell lung cancer The ETER701 trial demonstrates that a four-drug regimen, involving the addition of anti-angiogenesis therapy to immuno-chemotherapy, improves survival outcomes for extensive-stage small-cell lung cancer — but is more indeed better when it co...
Staging cancer provides important information about the outlook of the patient's condition and helps the doctor plan the best treatment. Although doctors stage other cancers from stage I to stage IV, small-cell lung cancer is classified into two stages. ...
Find out about TECENTRIQ® (atezolizumab) for the treatment of extensive-stage small cell lung cancer (ES-SCLC). See full safety for more information.
广泛期小细胞肺癌(SCLC)患者单独使用联合化疗。北美SCLC的标准治疗是给予卡铂或顺铂+依托泊苷。美国胸科医师学会(ACCP)、美国国家综合癌症网络(NCCN)和欧洲肿瘤医学学会(ESMO)的指南建议,广泛期病变的患者接受4-6个周期(但不>6个周期)的基于顺铂或卡铂的联合化疗(如顺铂+依托泊苷或依立替康)。[25,29,15] ...
Extensive-stage small-cell lung cancer is a therapeutically challenging disease. After more than two decades without clinical progress, the addition of programmed cell death protein 1 axis blockade to platinum-based chemotherapy has demonstrated sustained overall survival benefit and represents the current...
Small-cell lung cancer (SCLC) is a deadly cancer associated with smoke exposure that has neuroendocrine (NE) cell properties and is pathologically, molecularly, biologically and clinically very different from other lung cancers. While most patients with SCLC respond initially to cytotoxic therapy, almo...